Pazopanib for Metastatic Renal Cell Carcinoma: A Registry-based Analysis of 426 Patients

Pazopanib is approved for the first-line treatment of patients with metastatic renal cell carcinoma (mRCC). The present study was a retrospective registry-based analysis of 426 patients with mRCC treated with pazopanib as first-line targeted therapy.

The data were obtained from the Renal Cell Carcinoma Information system registry. Patient baseline parameters, treatment course and outcomes, and toxicity were analysed.

Median progression-free and overall survival were 12.9 (95% confidence interval(CI)=11.0-14.8) months and 33.2 (95% CI=29.9-36.4) months, respectively. Overall response rate and disease control rate were 25.1% and 57.4%, respectively. Adverse events led to discontinuation of treatment in 37 (12.1%) patients.

The results confirm that pazopanib is an effective and safe first-line targeted treatment in patients with mRCC. Both the International mRCC Database Consortium and the Memorial Sloan Kettering models were valid predictors of prognosis and nephrectomy was associated with improved survival.

Anticancer research. 2018 Jan [Epub]

Go Beyond the Abstract with a Commentary by the Author

Alexandr Poprach, Ondrej Fiala, Renata Chloupkova, Bohuslav Melichar, Radek Lakomy, Katarina Petrakova, Milada Zemanova, Katerina Kopeckova, Ondrej Slaby, Hana Studentova, Jindrich Kopecký, Igor Kiss, Jindrich Finek, Ladislav Dusek, Tomas Buchler

Department of Comprehensive Cancer Care, Masaryk Memorial Cancer Institute, Brno, Czech Republic., Department of Oncology and Radiotherapeutics, Faculty of Medicine and University Hospital in Pilsen, Pilsen, Czech Republic., Institute of Biostatistics and Analyses, Faculty of Medicine, Masaryk University, Brno, Czech Republic., Department of Oncology, Palacky University Medical School and Teaching Hospital, Olomouc, Czech Republic., Department of Oncology, First Faculty of Medicine, Charles University and General University Hospital, Prague, Czech Republic., Department of Oncology, Second Faculty of Medicine, Charles University and Motol University Hospital, Prague, Czech Republic., Department of Oncology, University Hospital in Hradec Králové, Hradec Králové, Czech Republic., Biomedical Center, Faculty of Medicine in Pilsen, Charles University, Pilsen, Czech Republic., Department of Oncology, First Faculty of Medicine, Charles University and Thomayer University Hospital, Prague, Czech Republic .

E-Newsletters

Newsletter subscription

Free Daily and Weekly newsletters offered by content of interest

The fields of GU Oncology and Urology are rapidly advancing. Sign up today for articles, videos, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.

Subscribe